UBTF‐internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemia
- 7 December 2022
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (4) , 202-209
Abstract
The prognosis of pediatric acute myeloid leukemia (AML) has improved via stratification therapy. However, relapse or death occurs in 30%–40% of cases. Novel genetic factors for pediatric AML need to be elucidated to improve prognosis. We detected recurrent internal tandem duplication in upstream binding transcription factor (UBTF‐ITD) in 1.2% (6/503) of Japanese pediatric patients with de novo AML. No UBTF‐ITD was detected in 175 adult patients with AML or in 65 cell lines that included 15 AML, 39 acute lymphoblastic leukemia, five chronic myeloid leukemia, and six neuroblastoma cell lines. All UBTF‐ITDs were found in exon 13 and shared a duplicated region. UBTF‐ITD was more frequently detected in patients with trisomy 8, FLT3‐ITD, WT1 mutation, and/or high PRDM16 expression (trisomy 8, 3/6; FLT3‐ITD, 5/6; WT1 mutation, 2/6; and high PRDM16 expression, 6/6). Gene expression patterns of patients with UBTF‐ITD were similar to those of patients with NUP98::NSD1 or FUS::ERG. Survival analysis of the AML‐05 cohort revealed that patients with UBTF‐ITD had worse outcomes than those without UBTF‐ITD (3‐year event‐free survival, 20% vs. 55%; 3‐year overall survival, 40% vs. 74%). Moreover, among the 27 patients with trisomy 8, all three patients with UBTF ‐ITD had a poor prognosis resulting in early events (relapse or non‐complete remission) within 1 year. Our findings suggest that UBTF‐ITD may be a novel and significant prognostic factor for pediatric patients with AML.Keywords
This publication has 15 references indexed in Scilit:
- The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactionsNature Medicine, 2017
- Trisomy 8 in pediatric acute myeloid leukemia: A NOPHO‐AML studyGenes, Chromosomes and Cancer, 2016
- High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3‐ITD,KMT2A‐PTD, and NUP98‐NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML‐05 trialBritish Journal of Haematology, 2015
- High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AMLLeukemia, 2015
- Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in childrenLeukemia, 2013
- Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapyBlood, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study GroupJournal of Clinical Oncology, 2009
- Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: A study of the Japanese childhood AML Cooperative Study GroupPediatric Blood & Cancer, 2007
- FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidyBlood, 2003